
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. non-small cell lung cancer (NSCLC) therapeutics Market**

According to Intelli, the U.S. non-small cell lung cancer (NSCLC) therapeutics Market size was valued at USD 5,478.23 Million in 2024 and is projected to reach USD 14351.01 million by 2032, growing at a CAGR of 13.32% from 2025 to 2032.



NSCLC is the most prevalent form of lung cancer in the U.S, accounting for approximately 85% of all lung cancer cases. Lung cancer remains the deadliest cancer in the U.S., and NSCLC accounts for the majority of this mortality despite improvements in treatment and early detection. Each year, tens of thousands of Americans are diagnosed with this aggressive disease, often at advanced stages where curative options are limited. It encompasses a diverse range of tumors including adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Some risk factors associated with NSCLC are smoking, exposure to carcinogens, air-pollution, genetics and history of lung disease. Symptoms of NSCLC often develop gradually and may be subtle in the early stages, which can delay diagnosis. One of the most common signs is a persistent cough that worsens over time or does not go away. Other respiratory symptoms include shortness of breath, wheezing, chest pain that intensifies with deep breaths or coughing, and hemoptysis. Systemic symptoms like unintentional weight loss, loss of appetite, and general weakness are also common and may indicate more advanced disease. In some cases, swelling of the face or neck can occur due to tumor pressure on major blood vessels. A comprehensive response to NSCLC must leverage multidisciplinary collaboration, advance early detection technologies, and promote healthcare equity to meaningfully reduce disease burden and improve quality of life.

**U.S. non-small cell lung cancer (NSCLC) therapeutics Market Definition**

NSCLC highlights the urgent need for early detection, equitable access to care, and continued innovation in treatment. The U.S. non-small cell lung cancer (NSCLC) therapeutics market refers to the segment of the pharmaceutical and biotechnology industry focused on the research, development, production, and commercialization of drugs and treatment modalities specifically targeting NSCLC. In 2023, the U.S. held the largest market share in the region, driven by a growing population exposed to air pollution and a high prevalence of smoking-related habits.

A close-up of hands holding a tablet and a pen

Description automatically generated

**U.S. non-small cell lung cancer (NSCLC) therapeutics Market Overview**

The U.S. non-small cell lung cancer (NSCLC) therapeutics market has experienced notable expansion, fueled by innovative treatment developments and an increasing number of NSCLC cases. Collaborations between biotech firms and research institutions are expected to further accelerate the introduction of groundbreaking therapies. This market includes a range of therapeutic approaches such as chemotherapy, targeted therapy, immunotherapy, and combination regimens. It comprises both branded and generic drugs, emerging biologics, and pipeline candidates in various stages of clinical development. Pharmaceutical companies are heavily investing in R&D to develop next-generation therapies. However, the U.S. NSCLC therapeutics market faces several key challenges that hinder its full potential. One of the most pressing issues is the high cost of advanced therapies, including targeted drugs and immunotherapies, which can limit accessibility for many patients. Furthermore, the development of resistance to existing treatments like EGFR or ALK inhibitors poses a major clinical hurdle, often requiring patients to switch therapies. In addition, limited access to healthcare in rural and underserved areas often leads to delayed diagnosis and poorer treatment outcomes. Addressing these obstacles will be significant for sustaining growth and improving outcomes in the NSCLC treatment.

**U.S. non-small cell lung cancer (NSCLC) therapeutics Market Segmentation Analysis**

U.S. non-small cell lung cancer (NSCLC) therapeutics Market is segmented based on cancer type, therapy type, route of administration, and end users. These segments are helpful to understand market dynamics, identify growth opportunities, and target key stakeholders effectively.

**U.S. non-small cell lung cancer (NSCLC) therapeutics Market, By cancer type**

* **Adenocarcinoma**
* **Squamous cell carcinoma**
* **Large cell carcinoma**

A close-up of hands holding a tablet and a pen

Description automatically generatedU.S. non-small cell lung cancer (NSCLC) therapeutics Market can be segmented by cancer type into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each exhibiting unique clinical characteristics and treatment responses. Among these, adenocarcinoma is the most prevalent subtype, accounting for approximately 45–50% of all NSCLC cases in the U.S. On the other hand, squamous cell carcinoma represents around 20–35% of NSCLC cases, typically linked to a history of smoking. It usually occurs in the central parts of the lungs. Large cell carcinoma is the least common subtype, making up about 5%–10% of cases. It is known for its aggressive nature and poor differentiation, posing challenges in diagnosis and treatment.

**U.S. non-small cell lung cancer (NSCLC) therapeutics Market, By therapy type**

* **Chemotherapy**
* **Targeted Therapy**
* **Immunotherapy**
* **Combination Therapy**
* **Radiation Therapy**
* **Others**

Based on therapy type, U.S. non-small cell lung cancer (NSCLC) therapeutics Market comprises of chemotherapy, targeted therapy, immunotherapy, and combination therapy. Each segments have the crucial role in evolving treatment landscape. Chemotherapy, the cornerstone of NSCLC treatment, remains widely used, particularly in patients without actionable mutations or in combination regimens. Now a days, targeted therapy is dominating as they are designed to inhibit specific genetic alterations such as VEGF**,** EGFR, ALK, and KRAS mutations. This therapy including VEGF inhibitors (Bevacizumab, Ramucirumab), EGFR inhibitors (afatinib, Erlotinib, Lazertinib, dacomitinib, gefitinib, Osimertinib), ALK inhibitors (Alectinib, ceritinib, ensartinib, brigatinib), & KRAS inhibitors (Adagrasib, Sotorasib), play a massive role, approximately 30–40% in U.S. non-small cell lung cancer (NSCLC) therapeutics Market. Immunotherapy, particularly immune checkpoint inhibitors like PD-1/PD-L1 inhibitors, has revolutionized treatment for advanced-stage NSCLC, notably extending survival in select patients. Lastly, Combination therapies, particularly those integrating immunotherapy with chemotherapy or using dual targeted agents, are becoming increasingly common in NSCLC. A widely used combination A close-up of hands holding a tablet and a pen

Description automatically generatedregimen involves pembrolizumab (a PD-1 immune checkpoint inhibitor) given with platinum-based chemotherapy in first-line treatment for metastatic NSCLC patients without actionable genetic mutations. This combination leverages the ability of chemotherapy to kill rapidly dividing cancer cells while allowing immunotherapy to activate the body’s immune system to attack residual tumor cells. Dual targeted therapy is also emerging as a promising strategy for patients with identifiable genetic mutations. Osimertinib, an EGFR inhibitor, is being evaluated in combination with agents like bevacizumab, an anti-VEGF therapy, to help delay disease progression and overcome resistance in cases of EGFR-mutated NSCLC.

**U.S. non-small cell lung cancer (NSCLC) therapeutics Market, By route of administration**

* **Oral**
* **Intravenous (IV**)

The U.S. NSCLC therapeutics market can be segmented by route of administration into oral and intravenous (IV) therapies, each with distinct clinical and patient-care implications**.** Oral administration has gained significant traction in recent years, particularly with the rise of targeted therapies such as osimertinib (EGFR inhibitor) and alectinib (ALK inhibitor), which are typically formulated as tablets or capsules. These oral agents offer greater convenience, improved patient compliance, and reduced need for hospital visits.On the other hand, intravenous therapies remain essential for treatments such as chemotherapy and immunotherapy, which require controlled administration in clinical environments**.**

**U.S. non-small cell lung cancer (NSCLC) therapeutics Market, By End users**

* **Hospitals**
* **Speciality clinics**
* **Others**

The U.S. non-small cell lung cancer (NSCLC) therapeutics market is segmented by end users into hospitals, specialty clinics, and others, each playing a vital role in treatment delivery and patient management. Hospitals dominate the market share for their comprehensive care infrastructure, advanced diagnostic capabilities. They are responsible for first-line treatment and management of advanced-stage NSCLC cases. Specialty clinics, A close-up of hands holding a tablet and a pen

Description automatically generatedincluding oncology-focused centers, are gaining attention as they offer specialized care, personalized treatment plans. The others category includes home care settings, ambulatory surgical centers, and outpatient infusion centers, which are becoming more relevant with the increased use of oral targeted therapies and home-based care models.

**Key Players**

The “U.S. non-small cell lung cancer (NSCLC) therapeutics Market " study report will provide valuable insight emphasizing the U.S market. The major players in the market are Pfizer Inc, Sanofi, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., Bristol Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson., Amgen Inc., AstraZeneca, Teva Pharmaceutical Industries Ltd., Celgene Corporation, Eisai Inc among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In May. 2024 Pfizer Inc. unveiled extended follow-up data from its Phase 3 CROWN trial, which evaluated LORBRENA against XALKORI for treating ALK-positive advanced non-small cell lung cancer (NSCLC). The results showed a remarkable 81% reduction in disease progression for patients treated with LORBRENA, highlighting its long-term effectiveness and potential as a superior first-line therapy for this form of lung cancer.
* In March, 2024 the U.S. FDA approved Amivantamab as a first-line therapy for patients with locally advanced or metastatic NSCLC.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. non-small cell lung cancer (NSCLC) therapeutics Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the U.S. non-small cell lung cancer (NSCLC) therapeutics Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. NON-SMALL CELL LUNG CANCER (NSCLC) THERAPEUTICS MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. NON-SMALL CELL LUNG CANCER (NSCLC) THERAPEUTICS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. NON-SMALL CELL LUNG CANCER (NSCLC) THERAPEUTICS MARKET, BY CANCER TYPE**

* 1. Overview
  2. A close-up of hands holding a tablet and a pen

     Description automatically generatedAdenocarcinoma
  3. Squamous cell carcinoma
  4. Large cell carcinoma

1. **U.S. NON-SMALL CELL LUNG CANCER (NSCLC) THERAPEUTICS MARKET, BY THERAPY TYPE**
   1. Overview
   2. Chemotherapy
   3. Targeted Therapy
   4. Immunotherapy
   5. Combination Therapy
   6. Radiation Therapy
   7. Others

**7 U.S. NON-SMALL CELL LUNG CANCER (NSCLC) THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION**

* 1. Overview
  2. Oral
  3. Intravenous (IV)

1. **U.S. NON-SMALL CELL LUNG CANCER (NSCLC) THERAPEUTICS MARKET, BY END USERS**
   1. Overview
   2. Hospitals
   3. Speciality clinics
   4. Others
2. **U.S. NON-SMALL CELL LUNG CANCER (NSCLC) THERAPEUTICS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. A close-up of hands holding a tablet and a pen

      Description automatically generatedKey Developments Stratigies
3. **COMPANY PROFILES**
   1. **Pfizer Inc.**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
   2. **Sanofi**

10.2.1 Overview

* + 1. Financial Performance
    2. Product Outlook
    3. Key developments
  1. **Novartis AG**
     1. Overview
     2. Financial Performance

10.3.3Product Outlook

10.3.4 Key developments

* 1. **Bayer AG**
     1. Overview
     2. 10.4.2Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Eli Lilly and Company**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  3. **Merck & Co**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Bristol Myers Squibb**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **AbbVie Inc**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **F. Hoffmann-La Roche AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  8. **Amgen Inc.** 
     1. A close-up of hands holding a tablet and a pen

        Description automatically generated Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  9. **AstraZeneca**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  10. **Teva Pharmaceutical Industries Ltd**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  11. **Celgene Corporation**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  12. **Eisai Inc**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments

1. A close-up of hands holding a tablet and a pen

   Description automatically generated**KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

12.1 Related Research